Summary: Rachel Yehuda, Ph.D., discusses the therapeutic potential of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) in the Mount Sinai Road to Resilience podcast. Dr. Yehuda is Director of the Center for Psychedelic Psychotherapy and Trauma Research at Icahn School of Medicine at Mount Sinai and is partnering with MAPS for an upcoming clinical trial at the U.S. Department of Veterans Affairs (VA), pending institutional and regulatory approvals.
Originally appearing here.
Rachel Yehuda, PhD, has been at the forefront of trauma research and treatment for three decades. Her pioneering work with populations including military veterans and Holocaust survivors has illuminated the biology of post-traumatic stress disorder (PTSD). But despite scientific advances, PTSD remains famously difficult to treat. Even “gold standard” cognitive-behavior approaches have been largely ineffective. In this interview, Dr. Yehuda talks about the therapeutic potential of psychedelic-assisted psychotherapy and describes her journey from skeptic to advocate for more research.
Dr. Yehuda is Professor of Psychiatry and Neuroscience, and Director of The Center for Psychedelic Psychotherapy and Trauma Research at the Icahn School of Medicine at Mount Sinai. She is also the Vice Chair for Veterans Affairs in the Department of Psychiatry as well as Director of the Traumatic Stress Studies Division.